Liraglutide safety and tolerability evaluated in healthy Japanese males at 20 and 25 µg/kg doses

Type 2 Diabetes Mellitus (T2DM) and obesity are global health challenges, with liraglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist, established as a treatment. While its efficacy is well-documented, drug development requires rigorous assessment across diverse populations due to potential genetic, metabolic, and lifestyle differences influencing drug pharmacokinetics and pharmacodynamics. Understanding the safety profile in specific ethnic groups, such as Japanese individuals, is crucial for ensuring appropriate dosing and minimizing adverse events, addressing a key gap in global drug translation.

This clinical trial investigated the safety and tolerability of liraglutide in healthy Japanese male volunteers. Participants received either 20 µg/kg or 25 µg/kg liraglutide. The primary objective was to assess the incidence and severity of adverse events, along with other safety parameters. The abstract does not specify the number of participants, the route of administration, the frequency of dosing (e.g., single dose vs. multiple), or the duration of the study.

The abstract for this study does not provide specific numerical results regarding the safety and tolerability of liraglutide. Typically, such a trial would report the frequency and type of adverse events, changes in vital signs, laboratory parameters, and potentially pharmacokinetic data such as Cmax and AUC for each dose group. Without these details, it is not possible to quantify the observed safety profile or draw conclusions about dose-dependent effects.